CD8A and pancreatic neoplasm: To test this, we depleted T cells using anti-CD4 and anti-CD8 antibodies (200 mg/mouse) in 4.5 weeks old PKT mice treated with vehicle or Uro A, and pancreatic tumors were harvested for endpoint analysis (after 3 weeks), or the treatment was continued until mice were moribund (Fig. 3J).